Member Info for NFTs

3 people like your post Soup ? Are they the other 3 accounts you have here on LSE?

Care to explain where you see Full year results? It’s always been half yearly in December and more often the time where they raise cash.

As usual you hide when wrong.

Think you will need to check again lol 😂

Even more serious as they need to show the business can continue for another year financially. Eeeekkk

They will need it done to show support he business can function after the half yearlys in December

December

Day after day you struggle to offload any basic amount but you can buy by the bucket load.

How many wait to try and escape. Been like it all year!

Is anyone surprised that the potential for AVACTA to be approached by BP?

It’s been ongoing with a massive platform which upon confirming that it works back in January and has continued to confirm Precision is now proven 100% along with AVA6k now proving efficacy on tumours!! One particular STS tumour of significance is continuing to shrink! Potentially showing an immune action by the body or AVA6k is doing it alone?

It only had to improve on toxicity to become the got-to for treatment but it’s smashing the doors down all over the place!!

So people are surprised if a BP approach’s now lol 😂

Of course they are coming and it won’t be one will it!

They will all want the platform and 10 billion is peanuts but £30 a share would imo do it!

Obviously we all want maximum but that will take years and a major. Humanity does not have the time and it’s important to hurry this groundbreaking work up.

£30 and I’ll be laughing happy for sure. 2300% is a good return from todays SP.

Roll on data and let’s see what may happen here.

I wouldn’t be surprised if AZ got wind of others coming forward that it pulls them in to come forward also along with others.

I think the litmus moment of catapulting this SP into the 10’s x tables is happening behind the closed doors waiting on that data to be presented before they emerge.

Sound’s immediately like a complete fail!!

Massively overpriced, over hyped mediocre products.

Too expensive now closing deals to be able to sell their product cheaper without others seeing the price.

Like Air New Zealand where you cannot tell what they flog them for to the partner .

This product is too expensive. When it comes to choice fever is better cheaper and available mass market.

This small tiny market, hard work, over priced, mediocre. End of its business plan is a fail!! Imo

That is there for progressive fluff to keep people entertained. It makes you feel progress and they use it as bait.

All about trying to keep investors interested as they struggle to bring in material info with no money to drive anything.

NXP001 bait dropped next will be NXP004 bait after that a cash raise and then if miracles are possible they find something tangible next year for NXP002.

These are only my workings nothing official and guesstimate on running operating costs etc.

£259,000 cash

£22,000 average x 7

£158,000 Lanstead payments

Tax back from government support on tests £90,000 approx

£70,000 placing

Total £577,000

Less £350,000 test NXP002

Less accounting and listing costs

£50,000

Less patents agent costs £30,000

BOD fees £60,000

Travel and expenses £20,000

Total left £67,000

I’m fully aware of the silly rat route Anne and Co dragged us down. Was against it from the very start. Destroyed the company.

I am also very aware of the exceptionally limited studies done after to try rescue the company.

They need more as per last RNS.

They are only in consultation period with interested parties who are asking for further work.

This is the problem NFX has no business anymore just a virtual office on screens.

They need money to do the requests for parties.

As I say deal or placing. Take your pick.

Better enable, not will enable!!!

Additional data! Not current data!! Last update.

They need cash they need data. End of.

“The net positive impact on our cash position will better enable the Company to progress our core NXP002 and NXP004 programmes and respond to requests for additional data as we continue partnering interactions for these programmes."

You have two options.

Placing or a deal by next results imo

So from past experience take your pick lol

Results in December will be interesting on costs spent if further trials have been done.

They raise 70k sold few quid in NXP001 the other day obviously keeping the lamps on.

December is the popular month for raise.

So safely say a placing is inbound. 0.2p again? We shall see.

What’s made up? Do you know what you are invested in?

“ Next Steps

Following the success achieved in these studies the Company's next steps include:

· Expansion of the current studies to include tissue from further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations in multiple patients; and

· Formally commencing the NXP002 partnering process now that Company has the minimum dataset required to support NXP002's development as an inhaled treatment for IPF, for use alongside SoC's.”

I guess they have to do studies for anybody remotely interested who will want to check the data and the prior issues in duration which they had in rats.

Human sliver of lung tissue was a quick test. The human model testing is far more expensive than rat data.

Anne B spent £1.5 million taking the company down the failed rat route.

Reason being is pharmaceuticals use that data as standard when looking for purchase of drug companies. So the limited tiny get out of jail lung tissue model they did after is probably too limited.

Therefore I’d expect interested parties need further work.

The problem is who pays! Won’t be NFX as they don’t have the cash model now.

So according to the telegram group, further studies have been completed? Yet the BOD do not wish to publish the results on NXP002?

What studies?

How much did that take out of the few pennies they have?

Why would you then not publicly publish this on a publicly listed company?

Shareholders should be informed or was the data not what they hoped for hence the removals before of the duration in rats which failed then tried again but pulled it halfway through and switched direction to combined SOC therapy rather than standalone treatment.

It takes nothing for a company to explain ongoings. They want to engage their shareholders and others with this business. The problem is they have always hidden anything bad from investors. They have told things with such vagueness that it’s always painted in a rosey form.

I don’t expect gloom but the fact this patent has been amended due to refusal. The fact they have against their will removed certain items due to refusal. Take nothing to play with a straight bat especially after lessons learned.

What I highlight is nothing has been learned and games are being continued.

NXP001 is now out of equation.

NXP004 reduces the amount of required powder!! That’s it! So how appealing is that for acquiring longer patent utilisation yet anyone else can just use the original powder lol

NXP002 requires further test before Phase 1

It’s now only a combination treatment to support SOC although someone with larger products maybe able to sort out the issue with duration.

NFX ran out of cash thanks to stubborn management and personal infighting leaving people to go in bad ways.

Bridges badly burnt all over the place.

This idea they will get some massive deal at this stage and position is ridiculous. They would just be happy to pass on the company as a going concern at cost to keep it moving towards success.

Every day that goes by now that couple 100k they have left will pay only basic listing operating regulatory costs for next period. No deal soon and they may have one raise left in the pipe.

Anyway

Love NFX it’s going to make me so rich 🤑 I won’t need to deliver papers anymore on my skateboard and walk dogs.

I own two

And?

Enjoy your evening and I’m sure it will come good one day again. Such fun

Love NFX really great company.